Raptor Pharmaceutical Corp.'s program to advance RP103 (cysteamine bitartrate delayed-release) in pediatric nonalcoholic steatohepatitis (NASH) "has always been a little bit left of center," president and CEO Julie Anne Smith maintained Monday. "Our core competency is in rare diseases. Read More
Lion Biotechnologies Inc., of New York, said it opened enrollment in a phase II trial of lead candidate LN-144 for the treatment of refractory metastatic melanoma. Read More
Kite Pharma Inc., of Santa Monica, Calif., said it expanded its agreement with the Netherlands Cancer Institute (NKI). Kite will receive an exclusive option to license a number of T-cell receptor gene sequences to develop and commercialize cancer immunotherapy candidates targeting solid tumors. Read More
LONDON – Acacia Pharma Ltd. will go public on the London Stock Exchange with the aim of raising £150 million (US$231 million) to complete development and begin commercialization of its two lead products for treating postoperative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Read More
Researchers have identified smac mimetics as a class of cancer drugs that synergized with histone deacetylase (HDAC) inhibitors to flush HIV out of hiding in infected T cells. The results suggest that smac mimetics could help achieve one of the major goals of current HIV research – an eradication cure. Read More
BOSTON – Biopharm America, designed to spur strategic relationships by way of a web-based service that sets up face-to-face meetings and more, kicks off today with 457 companies, 686 delegates, and 771 licensing opportunities on the roster as of last Friday. Read More
DUBLIN – Sanofi SA remains on track to complete a fourth-quarter regulatory submission of Lixilan, a fixed-ratio combination of its basal insulin (Lantus; insulin glargine) and its glucagon-like peptide 1 (GLP-1) receptor agonist Lyxumia (lixisenatide), on the back of a positive readout from the second of two phase III trials in type 2 diabetes patients. Read More
BOGOTA, Colombia – The links between the biotech sectors in Latin America and the Middle East and North Africa (MENA) remain shallow, even if industry stakeholders in both sides believe in the potential the relationships represent. Read More
The FDA will begin exercising its authority next month to destroy drugs valued at $2,500 or less that have been refused admission into the U.S. under the Federal Food, Drug and Cosmetic Act. Read More
